Cargando…

P054: The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma

Detalles Bibliográficos
Autores principales:	Visentin, Andrea, Ruggeri, Edoardo, Frezzato, Federica, Pizzi, Marco, Cellini, Alessandro, Angotzi, Francesco, Cavarretta, Chiara Adele, Ruocco, Valeria, Pravato, Stefano, Severin, Filippo, Facco, Monica, Manni, Sabrina, Piazza, Francesci, Trentin, Livio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Genomics, Biology & Microenvironment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621490/ http://dx.doi.org/10.1097/01.HS9.0000890784.88764.fa

Ejemplares similares

P1076: A RETROSPECTIVE ANALYSIS ON OLD AND EMERGING PROGNOSTIC FACTORS IN CLASSICAL HODGKIN’S LYMPHOMA IN THE PET-GUIDED ERA
por: Cellini, A., et al.
Publicado: (2022)

P005: Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study.
por: Visentin, Andrea, et al.
Publicado: (2022)

Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells
por: Cellini, Alessandro, et al.
Publicado: (2023)

P1075: ADVANCED-STAGE CHL INTERNATIONAL PROGNOSTICATION INDEX: EXTERNAL VALIDATION IN A SINGLE-CENTER RETROSPECTIVE PATIENT DATASET AND COMPARISON TO THE HASENCLEVER IPS
por: Cellini, Alessandro, et al.
Publicado: (2023)

From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance
por: Visentin, Andrea, et al.
Publicado: (2022)

A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency
por: Visentin, Andrea, et al.
Publicado: (2022)

Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
por: Visentin, Andrea, et al.
Publicado: (2020)

Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia
por: Frezzato, Federica, et al.
Publicado: (2021)

Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases?
por: Mouawad, Nayla, et al.
Publicado: (2023)

P047: Predictive role of the Hodgkin lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group
por: Prochazka, Vit, et al.
Publicado: (2022)

P043: Molecular pathogenesis of Hodgkin lymphoma
por: Beeck, Lilian, et al.
Publicado: (2022)

Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2
por: Spinello, Zaira, et al.
Publicado: (2021)

P038: HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma
por: Müller-Meinhard, Berit, et al.
Publicado: (2022)

P035: CRISPR/Cas9-mediated knockout reveals an important role of CD30 in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma
por: Kilian, Annika L., et al.
Publicado: (2022)

T026: Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma
por: Karihtala, Kristiina, et al.
Publicado: (2022)

P045: Plasma proteome profiling of cardiotoxicity in patients with Hodgkin lymphoma
por: Ulfstedt, Johan Mattsson, et al.
Publicado: (2022)

P046: Preclinical evaluation of novel repurposed drug combinations in Hodgkin lymphoma
por: Lohmann, Mia, et al.
Publicado: (2022)

P040: LINE-1 reverse transcriptase activity in Hodgkin lymphoma cells
por: Wadel, Annika, et al.
Publicado: (2022)

P048: Predictors of risk of relapse in classic Hodgkin lymphoma by flow cytometry
por: Fromm, Jonathan, et al.
Publicado: (2022)

P042: Metabolic regulation of adaptive response to arginine deprivation in Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2022)

P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
por: Mulder, Tom A., et al.
Publicado: (2022)

P044: PIM kinases support protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma
por: Szydłowski, Maciej, et al.
Publicado: (2022)

P033: Clinical significance of the severity of THRLBCL-like areas in nodular lymphocyte predominant Hodgkin lymphoma
por: Shupletsova, Irirna, et al.
Publicado: (2022)

P056: Variants of the transcription factor ONECUT2 regulate gene expression in Hodgkin Lymphoma cells
por: Lein, Patricia, et al.
Publicado: (2022)

P052: Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)
por: Xagoraris, Ioanna, et al.
Publicado: (2022)

In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment
por: Severin, Filippo, et al.
Publicado: (2019)

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases
por: Visentin, Andrea, et al.
Publicado: (2017)

P036: Detection of recurrent somatic variants in cell-free DNA as a tool for disease monitoring in Hodgkin lymphoma
por: Grohmann, Jan, et al.
Publicado: (2022)

P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma
por: Seifert, Nicole, et al.
Publicado: (2022)

T027: High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years
por: Diepstra, Arjan, et al.
Publicado: (2022)

P051: Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers
por: Piperidou, Alexia, et al.
Publicado: (2022)

P034: Correlation between MTV, TLG and Serum TARC Concentration in Classical Hodgkin Lymphoma during First-Line Treatment
por: Romano, Ilaria, et al.
Publicado: (2022)

P039: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma
por: Grund, Johanna, et al.
Publicado: (2022)

P031: CD4+ T cells in close proximity to Hodgkin-Reed Sternberg cells are antigen experienced, polyclonal and display an exhausted phenotype
por: Veldman, Johanna, et al.
Publicado: (2022)

P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma
por: Mammadova, Laman, et al.
Publicado: (2022)

P053: The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)
por: Xagoraris, Ioanna, et al.
Publicado: (2022)

Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases
por: Angotzi, Francesco, et al.
Publicado: (2022)

P055: Validation of the tumor cell-specific rearranged IgG-encoding circulating cell-free DNA for the treatment response monitoring in patients with classic Hodgkin lymphoma
por: Buhtoiarov, Ilia, et al.
Publicado: (2022)

Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma
por: Manni, Sabrina, et al.
Publicado: (2021)

P041: Low percentage of T lymphocytes in Hodgkin’s Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status
por: Korin, Laura, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j6qtavvhhmblu3jaqou01md6o1